Topic: chronic obstructive pulmonary disease (COPD)
The partners will work out of a joint lab at Brigham and Women's Hospital in Boston that will receive more than $30 million over the next five years.
Hillrom will buy former Fierce 15 winner Breathe Technologies, maker of a wearable ventilator for people with lung conditions such as COPD.
The appointments are part of Verona’s efforts to prepare for phase 3 development of ensifentrine in chronic obstructive pulmonary disease.
Spire Health launched an innovative study to develop digital biomarkers to predict COPD exacerbations and hospitalizations.
The study linked QVM149 to statistically significant improvements in lung function, leading Novartis to talk up its mooted blockbuster.
Pulmonx has secured $65 million in new equity financing for its global commercialization efforts through a round led by Ally Bridge Group.
In our EuroBiotech roundup this week, Hookipa prices IPO, Affimed eyes end of clinical hold and Cassiopea posts hair loss data.
The Fierce 15 company’s Loop wristband can measure heart rate, respiration and pulse oximetry, and is designed for patients with COPD.
Nuvaira has raised $79 million in equity financing to continue late-stage clinical development of its device-based treatment for COPD in the U.S.
The deal adds digital tools for conditions such as depression, chronic pain and opioid addiction to Livongo’s repertoire.